Tuesday, February 18, 2025
HomeCorporate FinanceFCF Healthcare & Life Sciences Enterprise Capital Monitor – USA – 10/2024...

FCF Healthcare & Life Sciences Enterprise Capital Monitor – USA – 10/2024 printed


FCF Fox Company Finance GmbH is delighted to publish the brand new “FCF Healthcare & Life Sciences Enterprise Capital Monitor – USA – 10/2024”.

The Monitor is a month-to-month printed overview of enterprise capital developments within the US Healthcare & Life Sciences sector.

As of the top of October 2024 we recognized the next present VC developments in the USA:

  • Whole Healthcare & Life Sciences funding reached EUR 7,381m
  • Biotech/Pharma acquired 60% of the whole funding quantity (EUR 4,442m) with oncology being the main indication (44%)
  • In October, Nelly (Germany) secured the best transaction quantity with EUR 100m, adopted by Purespring Therapeutics (United Kingdom) with EUR 95m and AgomAb (Belgium) with EUR 89m
  • Common Atlantic (United States) is essentially the most lively investor (by deal quantity in 2024), adopted by European Innovation Council Fund (Belgium) and Forbion (Netherlands)

To entry the total report, please click on right here.

By Mathias Klozenbücher und Johannes Hyperlink

RELATED ARTICLES

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Most Popular

Recent Comments